[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-neuropathy-due-to-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-neuropathy-due-to-chemotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,71,99,124,154,175,208,236,273,294,320],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100589812","balance4mobility-effects-of-walkasins-use-in-individuals-with-peripheral-neuropathy-and-balance-problems-100589812",false,"NCT06959277","Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems","Balance4Mobility: Effects of Walkasins Use on Clinical Outcomes of Gait and Balance Function in Individuals With Peripheral Neuropathy and Balance Problems - A Randomized Control Trial","Inclusion Criteria:\n\n* Able to understand and provide informed consent for him or herself\n* Age 55 and older, male or female\n* Able to complete all functional outcome measures without the use of an assistive device\n* Clinical diagnosis of peripheral neuropathy prior to participating in the study as documented in the participant's medical record or by physician's note. Individuals with chemo-induced peripheral neuropathy must be at least one-year post-chemotherapy, indicating that their PN has become a chronic condition.\n* Self-reported gait and balance problems\n* Foot size that allows the Walkasins to function appropriately\n* Willing to use the Walkasins device as recommended\n\nExclusion Criteria:\n\n* Ability to stand on one leg for at least 30 seconds (If the person can stand for at least 30 seconds, he\u002Fshe is excluded because his\u002Fher balance is likely not impaired enough to benefit from Walkasins.)\n* Self-reported acute thrombophlebitis, including deep vein thrombosis\n* Self-reported severe peripheral vascular disease\n* Untreated lymphedema\n* Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use\n* Self-reported, untreated fractures in the foot and ankle\n* Other neurological or musculoskeletal conditions that moderately or severely impact walking\n* Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins\n* Weight of more than 300 pounds\n* Inability to perceive vibration from Walkasins Haptic Module","ALL","55 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of their foot placement on the ground.\n\nResearchers will compare Walkasins users to a control group of participants who are not using Walkasins to see if the device improves the users' performance on some standing and walking tests. Control group participants will get Walkasins after six months of being in the study.\n\nDuring the study participants will be asked to do the following:\n\n* Answer questions about their medical history and balance.\n* Do some standing and walking tests. Some of the tests will be timed.\n* Attend study visits and participate in study phone calls.\n* Keep track of any falls and notify study staff if they fall.\n* Wear the Walkasins device on a regular basis.",[26,27,28,29,30],"Peripheral Neuropathies","Peripheral Neuropathy Due to Chemotherapy","Peripheral Neuropathy With Type 2 Diabetes","Balance Control in Elderly","Gait Disorders",[32,33,34],"Walkasins","Peripheral Neuropathy","Balance Problems","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-24","ACTUAL",{"date":41,"type":39},"2025-06-17",{"date":43,"type":20},"2027-12-31",{"name":45,"class":46},"RxFunction Inc.","INDUSTRY",6,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100573325","early-phase-1-exploring-the-benefit-of-topical-capsaicin-in-treating-pain-from-chemo-induced-peripheral-neuropathy-a-longitudinal-single-center-pilot-study-100573325","NCT06744816","Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study","Inclusion Criteria:\n\n* Participants diagnosed with pain of the lower extremity from chronic (\\>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center\n* Participants reporting baseline pain ≥ 4 (0-10 scale, NRS)\n* Participants age 18+\n* Participants who have completed chemotherapy within the last year at the time of enrollment.\n\nExclusion Criteria:\n\n* Participants with cognitive dysfunction\n* Participants with recent history (\\\u003C6 months) of drug or alcohol abuse\n* Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Participants with allergies to capsaicin or adhesives\n* Pregnant participants","18 Years",{"count":56,"type":20},20,[58],"EARLY_PHASE1","To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.",[27],{"date":62,"type":39},"2026-06-26",{"date":64,"type":39},"2025-12-11",{"date":66,"type":20},"2027-11-30",{"name":68,"class":69},"M.D. Anderson Cancer Center","OTHER",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100625496","phase-3-study-on-the-efficacy-and-safety-of-mecobalamin-in-preventing-taxane-related-peripheral-neuropathy-100625496","NCT07423390","Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed solid tumors, including but not limited to breast cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and melanoma;\n2. Age ≥18 years;\n3. Scheduled to receive adjuvant or neoadjuvant taxane-based chemotherapy (including paclitaxel, nab-paclitaxel, or docetaxel; as monotherapy or in combination) for early-stage disease, or has advanced disease with no prior chemotherapy;\n4. Life expectancy ≥3 months;\n5. ECOG performance status 0-2;\n6. Adequate major organ function (cardiac, hepatic, renal, and bone marrow function);\n7. Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Severe impairment of major organ function such that the participant cannot tolerate standard-dose chemotherapy;\n2. Pre-existing peripheral neuropathy or a history of peripheral neuropathy;\n3. Skin conditions (e.g., severe palmoplantar keratoderma, active skin infection) that may interfere with assessment of CIPN symptoms;\n4. Recent use of medications that may alleviate CIPN symptoms;\n5. Inability to swallow, intestinal obstruction, or other conditions that may affect drug absorption;\n6. Known hypersensitivity or allergy to mecobalamin;\n7. Pregnant or breastfeeding women.",{"count":78,"type":20},326,[80],"PHASE3","Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.",[27,83],"Peripheral Neuropathy, Chemotherapy-induced",[85,86,87,88],"Chemotherapy induced peripheral neuropathy","Mecobalamin","Taxane","Prevention","2026-04-25",{"date":91,"type":39},"2026-04-30",{"date":93,"type":39},"2026-02-24",{"date":95,"type":20},"2029-05-31",{"name":97,"class":69},"Qinghai Red Cross Hospital",4,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100600323","nerve-excitability-in-cisplatin-induced-peripheral-neuropathy-100600323","NCT07095998","Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","Evaluation of Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","Inclusion Criteria Cohort A:\n\n* Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.\n* Participants must have adequate hematologic parameters to allow chemotherapy.\n\nExclusion Criteria Cohort A:\n\n* Pre-existing peripheral neuropathy;\n* Family history of a genetic\u002Ffamilial neuropathy;\n* Any contraindication for treatment with cisplatin as determined by their primary oncologist;\n* Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;\n* Patients with cardiac or spinal stimulating devices;\n* Women who are pregnant or breastfeeding;\n* Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;\n* Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;\n* Patients not considered to be able to comply with the protocol.\n\nInclusion Criteria Cohort B:\n\n* Adults age ≥ 18 with a diagnosis of cis-PN.\n* The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy.\n\nExclusion Criteria Cohort B:\n\n* Pre-existing peripheral neuropathy;\n* Family history of a genetic\u002Ffamiliar neuropathy;\n* History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;\n* Patients with cardiac or spinal stimulating devices;\n* Women who are pregnant or breastfeeding;\n* Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;\n* Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;\n* Patients not considered to be able to comply with the protocol.",{"count":107,"type":20},60,[23],"This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.",[27,33,111,112],"Neurotoxicity Syndromes","Neuropathy",[27,33,111,112],"2026-04-18",{"date":116,"type":39},"2026-04-22",{"date":118,"type":39},"2026-01-31",{"date":120,"type":20},"2028-12-31",{"name":122,"class":69},"Ka-Wai Ho",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":70},"100628678","compression-therapy-of-hands-and-feet-for-the-prevention-of-taxane--or-oxaliplatin-induced-peripheral-neuropathy-100628678","NCT07464769","Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy","A Randomized Controlled Study of Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy","KompXX","Inclusion Criteria:\n\no Scheduled neurotoxic treatment in any of the following settings: Taxane cohort\n\n* Breast cancer patients planned for either neoadjuvant or adjuvant taxane treatment Oxaliplatin cohort\n* Rectal cancer patients planned for total neoadjuvant treatment including oxaliplatin\n* Colorectal cancer patients planned for adjuvant chemotherapy including oxaliplatin, without prior neoadjuvant oxaliplatin treatment\n* Understand written and oral Swedish.\n\nExclusion Criteria:\n\n* Previous neurotoxic chemotherapy\\* treatment\n* Distant metastases\n* Any psychiatric disorder or health disorder that causes an inability to make an informed consent to participate.\n* Any manifest clinically significant peripheral neuropathy according to treating physician.\n* Current lymphoedema in limbs requiring compression therapy.\n* Ongoing pregnancy.\n* Planned taxane or oxaliplatin treatment shorter than 8 weeks or longer than 26 weeks\n* Planned compression or cryotherapy of hands and\u002For feet during taxane or oxaliplatin\n\n  * Taxanes (docetaxel, paclitaxel, nabpaclitaxel), platinum components (carboplatin, oxaplatin, cisplatin), vinca-alkaloids (vincristine, vinblastine, vinorelbine, eribulin), bortezomid, thalidomide, antibody drug conjugate including vedotin or emtansine.",{"count":133,"type":20},358,[23],"Population Cohort 1 Taxane: Breast cancer patients; (neo-)adjuvant treatment Cohort 2 Oxaliplatin: Colorectal cancer patients; (neo-)adjuvant treatment Study design Multicentre, unblinded randomised controlled study Study rationale Chemotherapy-induced peripheral neuropathy is a dose-limiting side effect during treatment and cause persistent impairment and worsening of quality of life in cancer survivors.\n\nCompression therapy could be a plausible preventive intervention, although practice changing studies are lacking.\n\nAims To investigate if compression therapy of the hands and feet can reduce the prevalence of both acute and persistent CIPN symptoms caused by taxanes or oxaliplatin. Furthermore, to investigate if compression therapy impact the level of taxane or oxaliplatin dose reductions.\n\nEndpoints Primary endpoint\n\n* The difference in the occurrence of sensory chemotherapy-induced peripheral neuropathy (CIPN) Selected secondary endpoints\n* Key secondary endpoint: Difference in relative dose intensity of taxane respectively oxaliplatin.\n* The difference in the occurrence of motor and autonomic chemotherapy-induced peripheral neuropathy (CIPN).\n* Difference in occurrence of persistent patient-reported CIPN symptoms 1, 3 and 5 years after start of neurotoxic chemotherapy (EORTC CIPN20)\n* Health-related quality of life at baseline and after 1, 3, 5 years (EORTC QLQ C30) Exploratory endpoints\n* Prevalence of autonomic neurotoxicity after neurotoxic treatment, defined as increase of prevalence from baseline to one year after treatment.\n\nSubstudy\n\n• Development of pharmacogenetic risk prediction models of acute respectively persistent taxane induced peripheral neuropathy.\n\nSample size Randomisation 1:1, per site Taxane cohort 268 breast cancer patients, stratification on taxane type Oxaliplatin cohort 90 colorectal cancer patients, stratification on length of treatment Follow-up Patient-reported CIPN symptoms during treatment and at time point up to 5 years post-treatment.",[27],[138,139,140,141,142,88],"Breast cancer","Colorectal Cancer","Taxan","Oxaliplatin","Compression therapy","NOT_YET_RECRUITING","2026-03-06",{"date":146,"type":39},"2026-03-11",{"date":148,"type":20},"2026-04",{"date":150,"type":20},"2033-12-31",{"name":152,"class":153},"Region Jönköping County","OTHER_GOV",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":161,"targetDuration":162,"studyType":163,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":4},"100623933","validating-fish-oils-role-in-alleviating-bortezomib-induced-neuropathy-a-multi-method-study-integrating-big-data-experimental-and-clinical-research-100623933","NCT07403071","Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research","A Study Combining Big Data Mining With Experimental and Clinical Research to Validate the Alleviating Effect of Fish Oil on Bortezomib-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* (1) Aged 18 years or older, regardless of gender. (2) Diagnosed with multiple myeloma (MM) according to the \"Guidelines for the Diagnosis and Management of Multiple Myeloma,\" and scheduled to receive bortezomib as first-line therapy.\n\n  (3) Absence of baseline peripheral neuropathy prior to the initiation of bortezomib treatment.\n\n  (4) Provision of signed informed consent.\n\nExclusion Criteria:\n\n* (1) Patients with poor medication adherence. (2) Women who are pregnant or lactating. (3) Cases deemed ineligible by the investigator.",{"count":19,"type":20},"24 Months","OBSERVATIONAL","The goal of this study is to find out if taking fish oil by mouth can help prevent or lessen a side effect called peripheral neuropathy in patients who are being treated with the chemotherapy drug bortezomib.\n\nWe are mainly looking to answer one question: Can fish oil reduce the chances of getting this nerve damage, or make it less severe, for these patients?",[166,27],"Multiple Myeloma","2026-02-04",{"date":169,"type":39},"2026-02-11",{"date":171,"type":20},"2026-05-01",{"date":43,"type":20},{"name":174,"class":69},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":70},"100578130","feasibility-testing-of-a-tai-chi-program-for-chemotherapy-induced-peripheral-neuropathy-treatment-tct-100578130","NCT06807294","Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)","Inclusion Criteria:\n\n* Age 18 years old and older\n* Cancer survivors with no evidence of disease (cancer);\n* Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment;\n* A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia;\n* Answers \"yes\" to the following question: \"Do you feel as though your balance is affected from experiencing CIPN?\" or \"Are you afraid of falling as a result of your CIPN?\";\n* On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2\n* Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12);\n* Willing to adhere to requirement that no new pain medication be taken throughout the study period; and\n* Individuals receiving endocrine therapy or targeted\u002Fantibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate.\n\nExclusion Criteria:\n\n• Patients who have received physical therapy or Tai Chi training, specifically for CIPN, in the past three months.",{"count":182,"type":20},21,[23],"This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).",[186,27,26,112],"Chemotherapy Induced Peripheral Neuropathy (CIPN)",[33,188,189,190,191,192,193,194,195,196,197,198],"Chemotherapy Induced Peripheral Neuropathy","Cancer survivor","CIPN","Tai Chi","Balance training","Falls prevention","Non-pharmacological intervention","Mind-body exercise","Quality of life","Feasibility study","Pilot study","2026-01-27",{"date":201,"type":39},"2026-01-29",{"date":203,"type":39},"2026-01-16",{"date":205,"type":20},"2026-10-31",{"name":207,"class":69},"Dana-Farber Cancer Institute",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":70},"100605817","early-phase-1-neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy-100605817","NCT07167446","Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy","Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study","Inclusion Criteria:\n\n1. Patients with metastatic, locally advanced unresectable colorectal cancer patients planned to receive Ox based chemotherapy in metastatic setting (at least 3 months planned).\n2. Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.\n3. ECOG PS 0-2\n4. No prior platinum exposure\n5. No evidence of ongoing neuropathy of any grade at the time of enrollment\n6. Patients must have marrow and organ function appropriate for systemic therapy, as per physician's discretion, but liver function should meet criteria below:\n\n   1. Total Bilirubin: less than and\u002For equal to 1.5 X ULN\n   2. AST(SGOT)\u002FALT(SGPT): less than and\u002For equal to 3 X ULN (5 X ULN in patients with liver metastases\n7. Ability to understand and willingness to sign a written informed consent and HIPAA consent document.\n\n   Exclusion Criteria:\n8. Family history of genetic\u002Ffamilial neuropathy and personal history of ongoing neuropathy (any grade) or nervous system disease with the potential to affect cognition, Parkinson's disease, or multiple sclerosis.\n9. Routine use of recreational marijuana products (defined as \\> 4 times per month) or illicit drug use per self-reported history within the last 90 days. If using medical cannabis products, it should be stopped at least 1 week prior to inclusion.\n10. Known underlying liver disease (Child-Pugh B or C) or baseline elevation of total bilirubin greater than and\u002For equal to 1.5 x upper limit of normal based on screening laboratory values.\n11. 1Untreated brain metastases (can increase seizure risk), or treated brain metastases on anti-seizure medications.\n12. Patients being treated with anti-seizure or anti-psychotic medications. Patients with a prior history of anti-seizure medication use, who have been off treatment for more than 3 months, are eligible. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) is permitted.\n13. Concomitant treatment with strong inducers of CYP3A4 and\u002For strong inducers of CYP2C19.\n14. Underlying history of epilepsy\u002Frecurrent seizure disorder or unexplained seizure within past 6 months.\n15. Patients with current or lifetime diagnosis of schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \\& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022)\n16. Recent history or clinical concern for major depression with suicidal ideation as determined by investigator assessment at baseline\n17. Currently taking medications known to be contraindicated with Epidiolex -FDA-approved CBD (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate).\n18. Women who are pregnant or breastfeeding, and individuals of any sex who are capable of reproduction and unwilling to use an effective form of birth control (e.g., condoms, diaphragm, birth control pills, or IUD).\n19. Patients may not be receiving any other investigational agents.",{"count":216,"type":20},30,[58],"This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.",[220,221,27],"Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","Metastatic Colorectal Cancer (CRC)",[223,224,225,226],"Oxaliplatin-Induced Peripheral Neuropathy (OIPN)","Cannabidiol (CBD)","Colorectal Cancer (CRC)","Neuroprotection","2025-10-20",{"date":229,"type":39},"2025-10-22",{"date":231,"type":39},"2025-10-14",{"date":233,"type":20},"2028-09-07",{"name":235,"class":69},"Fox Chase Cancer Center",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":244,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":255,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100606060","effectiveness-of-a-therapeutic-exercise-program-with-specific-upper-limb-exercises-to-reduce-lymphedema-and-neuropathy-in-breast-cancer-patients-a-pre-post-study-lynma-100606060","NCT07170631","Effectiveness of a Therapeutic Exercise Program With Specific Upper Limb Exercises to Reduce Lymphedema and Neuropathy in Breast Cancer Patients: A Pre-post Study (LYNMA)","Effectiveness of a General Therapeutic Exercise Program Including Specific Upper Limb Exercises to Reduce Lymphedema and Peripheral Neuropathy Secondary to Oncological Treatment in Patients With Breast Cancer: A Pre-post Intervention Study (LYNMA)","LYNMA","Inclusion Criteria:\n\n* Patients receiving treatment for breast carcinoma.reatments include surgical procedures (breast-conserving surgery or mastectomy), axillary lymph node dissection, sentinel lymph node biopsy, radiotherapy, chemotherapy, and hormone therapy.\n* Participants must provide authorization from their primary care physician and\u002For oncologist to perform therapeutic exercise.\n* Diagnosis of lymphedema associated with stage I or II breast cancer (Stage 1 or mild: circumference difference less than 4 cm \\[volume difference 10-25%\\] compared to the healthy arm; Stage 2 or moderate: circumference difference between 4 and 6 cm \\[volume difference 25-50%\\] compared to the healthy arm).\n* A score of 4 or higher on the DN4 questionnaire (neuropathic pain)\n\nExclusion Criteria:\n\n* Lack of medical authorization.\n* Pre-existing cardiac pathology prior to cancer diagnosis.\n* Exacerbation of comorbidities.\n* Travel time exceeding 45 minutes to the location where the therapeutic exercise program is conducted.","FEMALE","35 Years","70 Years",{"count":216,"type":20},[23],"This study aims to evaluate the effectiveness of a therapeutic exercise program designed specifically for women with breast cancer. The program includes general exercises along with specific movements for the upper limb to help reduce common side effects of cancer treatment such as lymphedema (swelling of the arm) and neuropathy (nerve pain or numbness). Participants will undergo the exercise program and be assessed before and after to determine improvements in their symptoms and overall quality of life. The goal is to provide evidence that targeted physical therapy can improve recovery and well-being in breast cancer survivors.",[251,252,253,27,254],"Lymphedema Arm","Lymphedema Due to Radiation","Lymphedema, Breast Cancer","Peripheral Neuropathy in Breast Cancer Patient",[256,138,257,258,259,260,261,262,263],"Therapeutic exercise","Lymphedema","Peripheral neuropathy","Upper limb exercises","Oncology physiotherapy","Neural mobilization","Neurodynamic techniques","Peripheral nerve ultrasound","2025-09-12",{"date":266,"type":39},"2025-09-18",{"date":268,"type":20},"2026-01",{"date":270,"type":20},"2026-10",{"name":272,"class":69},"Universitat Internacional de Catalunya",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":280,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":70},"100540170","fall-risk-and-quality-of-life-in-individuals-with-cancer-treatment-related-peripheral-neuropathy-100540170","NCT06313359","Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.","Fall Risk and Quality of Life: Influence of Dual Task Performance, Cognition, and Sensorimotor Variables in Individuals With Cancer Treatment Related Peripheral Neuropathy.","Inclusion Criteria:\n\nExperimental group\n\n* Individuals 18 years and older\n* diagnosed with non- CNS cancer who underwent treatment and presents with peripheral neuropathy symptoms.\n\nControl group\n\n* age (+\u002F- one year) and gender matched individuals\n* no diagnosed peripheral neuropathy\n* No diagnosed cognitive symptoms.\n\nExclusion Criteria:\n\n* Unable to follow two step commands.\n* Unable to ambulate x 50 feet independently without use of an assistive device.\n* Unable to use a phone to send text messages.\n* Diagnosis of diabetic peripheral neuropathy\n* Diagnosis of CNS cancer.\n* Unable to speak\u002Funderstand English",true,{"count":282,"type":20},40,"The purpose of this research is to examine the impact of peripheral neuropathy on fall risk and quality of life in people who had cancer and neuropathy from cancer treatments. The investigators are interested to find out if the participant have any difficulty with thinking, feeling, balancing, or moving around that will contribute to risk for falls or quality of life. Investigators are also interested to see if the participants have any difficulty with doing two activities at the same time, such as walking and texting.",[27],"2025-09-02",{"date":287,"type":39},"2025-09-03",{"date":289,"type":39},"2024-03-30",{"date":291,"type":20},"2026-06-30",{"name":293,"class":69},"Texas Woman's University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":244,"minAge":54,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100603061","the-effect-of-cryocompression-on-peripheral-neuropathy-in-patients-receiving-chemotherapy-for-gynecological-cancer-100603061","NCT07131618","The Effect of Cryocompression on Peripheral Neuropathy in Patients Receiving Chemotherapy for Gynecological Cancer","CryoPN","Inclusion Criteria:\n\n* Applying to Mersin University Hospital Oncology Outpatient Clinic\n* Willing to participate and providing signed informed consent\n* Able to read and write in Turkish\n* Accessible and able to communicate\n* Citizen of the Republic of Türkiye\n* Diagnosed with gynecologic cancer (ovarian, endometrial, or cervical) and aged ≥18 years\n* Receiving weekly carboplatin + paclitaxel chemotherapy protocol\n* No subjective peripheral neuropathy symptoms before starting chemotherapy\n* No history of peripheral neuropathy related to previous taxane\u002Fplatinum-based chemotherapy protocols\n* No psychiatric disorders\n* No diseases that may cause peripheral neuropathy such as diabetes, rheumatoid arthritis, or fibromyalgia\n\nExclusion Criteria:\n\n* Not applying to the specified outpatient clinic\n* No gynecologic cancer diagnosis or younger than 18 years old\n* Not providing informed consent\n* Not receiving weekly carboplatin + paclitaxel chemotherapy protocol\n* Presence of subjective peripheral neuropathy symptoms before starting chemotherapy\n* History of peripheral neuropathy related to previous taxane\u002Fplatinum-based chemotherapy protocols\n* Presence of psychiatric disorders\n* Having diseases that may cause peripheral neuropathy such as diabetes, rheumatoid arthritis, or fibromyalgia",{"count":302,"type":20},78,[23],"Study Design:\n\nThis study is designed as a prospective, randomized controlled experimental study aiming to determine the effect of cryocompression therapy, applied during chemotherapy, on peripheral neuropathy symptoms in women with gynecologic cancers.\n\nResearch Hypotheses:\n\n* H₀: Cryocompression therapy has no effect on peripheral neuropathy.\n* H₁: Cryocompression therapy has an effect on peripheral neuropathy.\n\nStudy Population:\n\nThe study population will consist of women over the age of 18 living in Mersin, Türkiye, who are diagnosed with gynecologic cancer and undergoing chemotherapy between August 10 and December 31, 2025.",[306,27],"Gynecological Cancers",[308,309,310],"Gynecological cancer","cryocompression","peripheral neuropathy","2025-08-12",{"date":313,"type":39},"2025-08-20",{"date":315,"type":20},"2025-08-10",{"date":317,"type":20},"2025-12-31",{"name":319,"class":69},"Mersin University",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":327,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":70},"100329600","phase-2-botulinum-toxin-a-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-100329600","NCT03571334","Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy","Inclusion Criteria:\n\n1. Been diagnosed with breast cancer and undergone treatment with taxane based chemotherapeutic agents. Patients with metastatic and non metastatic disease are eligible.\n2. Have neuropathic pain with onset within 6 months of chemotherapy\n3. Must score \\>4 on DN4 scale, a scale with high specificity and sensitivity for differentiating neuropathic pain from somatic and nociceptive pain\n4. Age \\>18 years, male and\u002For female\n5. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. End Stage Renal Disease patients on Hemodialysis\n2. Female participants who are pregnant (positive urine pregnancy test), who have an infant they are breastfeeding, or intend to become pregnant within 6 months.\n3. History of peripheral neuropathy attributed to any cause other than chemotherapy\n4. Currently receiving chemotherapy, or having had received chemotherapy in the past 6 months\n5. Prior treatment with Botulinum Toxin A for any indication within the past 6 months\n6. Changes in neuropathic pain modulators within 1 month prior to enrollment or during the course of the trial. Participants who require rescue medications for breakthrough pain can be given so at the discretion of their provider.\n7. Hypersensitivity reaction to INA injection\n8. Distal muscle weakness and\u002For atrophy\n9. Active infection at injection site",{"count":282,"type":20},[328],"PHASE2","Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of taxanes and platinum derivative based chemotherapeutic agents, common in breast cancer treatment regimens. It can have a significant effect on both quality of life and treatment outcomes, often resulting in dose modifications and early treatment discontinuation. The use of IncobotulinumtoxinA (INA) ((Xeomin®, Merz) has recently been shown to be effective in the treatment of neuropathic pain via inhibiting the release of several neurotransmitters involved in pain signaling pathway.\n\nThe purpose of this study is to examine the efficacy and safety of intradermal INA injections for treatment of CIPN in breast cancer patients. The study will recruit a total of 40 participants, randomly assigned to receive either INA (Experimental group, n=20) or saline placebo injections (Control group n=20).\n\nPotential participants who have received chemotherapy for breast cancer will be screened for the diagnosis of peripheral neuropathy. After obtaining informed consent, participants will be further screened with the DN4 questionnaire, a clinician administered questionnaire that has a high level of sensitivity and specificity in discriminating neuropathic pain. Those study participants who score ≥4 on this tool will undergo nerve conduction studies to confirm the presence of peripheral neuropathy. Recruited study participants will then be randomized to treatment or control groups; the treatment group will undergo intradermal injections of INA (100 Units INA, total volume 5ml), and the control groups will undergo placebo injection with preservative-free normal saline (equal volume, 5mL). Total injection volume will be divided evenly and injected intradermally into a total of 50 sites on either the feet or hands (25 sites per limb).\n\nThe primary outcome will be the assessment of pain using the neuropathic pain scale (NPS) prior to intervention and at eight weeks post intervention. Secondary outcomes will include the change in NPS for each domain at additional time points: 2weeks, 4 weeks, 12 weeks, 6 months, the change in the Neuropathic Pain Impact on Quality of Life (NePIQoL) score at time points: 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and the incidence of treatment related adverse events within each cohort. Statistical analysis will be utilized to determine whether the injection of intradermal INA is effective in improving pain as measured by the NPS scales vs placebo.\n\nWe hypothesize that the study participants treated with INA will have lower NPS scores as compared to placebo.",[27],"2021-12-21",{"date":333,"type":39},"2021-12-23",{"date":335,"type":39},"2020-07-08",{"date":337,"type":20},"2024-12-31",{"name":339,"class":69},"Medical College of Wisconsin"]